2.955USD-23.25%Mkt Cap: 15.44M USDP/E: —Last update: 2026-05-26
MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. The company develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with devel…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap15.44M USD
Enterprise Value1.28M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-12.97M USD
Revenue/Share—
Last Price2.955 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees8
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-0.09
EV/Revenue—
P/S—
P/B1.24
EPS (TTM)-4.21
EPS (Forward)—
52W Range
0.966011% of range19.03
52W High19.03 USD
52W Low0.9660 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-243.26%
ROA-116.63%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-15.70M USD
CapEx (TTM)2.00K USD
FCF Margin—
FCF Yield-67.33%
Net Debt-13.54M USD
Net Debt/EBITDA0.98
Balance Sheet
Debt/Equity0.04
Current Ratio2.73
Quick Ratio2.65
Book Value/Sh2.310 USD
Cash/Share2.659 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateDec 31, 2019
Splits
Last Split1:11
Split DateDec 5, 2025
Analyst Consensus
Rating1.5 (Buy)
Target (Mean)19.33 USD
Target Range8.000 USD – 30.00 USD
# Analysts3
Ownership
Shares Out.5.16M
Float3.39M
Insiders34.50%
Institutions13.38%
Short Interest
Short Ratio0.6d
Short % Float2.39%
Short % Out.1.57%
Shares Short80.86K
Short (prev mo.)56.74K
Technical
SMA 501.439 (+105.3%)
SMA 2005.832 (-49.3%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)6.64M
Avg Vol (10d)15.36M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—